Panc02小鼠胰腺癌细胞系由Corbett等人通过在C57BL/6小鼠胰腺内植入携带3-甲基胆蒽的棉线，诱导导管腺癌形成，并通过连续皮下移植建立。 作为来源于小鼠胰腺导管腺癌的细胞系，Pan02细胞呈上皮样形态，具有贴壁生长特性，广泛应用于胰腺癌的生物学研究、药物筛选及肿瘤微环境模拟等领域。 将培养基（高糖DMEM + 5% 胎牛血清 + 1% 青霉素/链霉素）预热至37℃。 准备无菌的离心管和移液器，确保无菌操作环境，避免Panc02细胞污染。 从液氮中取出Panc02细胞冻存 …

本细胞的完全培养液可以自行配制，推荐选购碧云天生产的Pan02细胞完全培养液 (含血清等) (C7489C），该培养液已经添加了优质胎牛血清和所需的添加剂如双抗以及细胞培养所必须的添加剂，可以直接使用，让细胞无须驯化就能正常生长。

PAN 2.0 integrates services currently spread across multiple platforms into a single unified portal. It also introduces paperless processes, makes PAN/TAN allotment/updates/corrections free of charge (e-PAN sent to registered email), and charges a nominal fee for physical PAN cards (₹50 domestic, ₹15 + postal charges for international ...

本细胞的完全培养液可以自行配制,推荐选购碧云天生产的Pan02 细胞完全培养液( 含血清等) (C7489C),该培养液已经添加了优质胎牛血清和所需的添加剂如双抗以及细胞培养所必须的添加剂,可以直接使用,让细胞无须驯化就能正常生长。

源井生物提供的小鼠胰腺癌细胞 (Pan-02)由ATCC、ECACC和DSMZ等各大权威细胞库引进，细胞代次低、活性高、状态好，可提供STR鉴定报告，保证细胞身份准确。

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer.

在超净台内把培养瓶里的培养液倒至废液缸, 用1× PBS(T25 cm2 培养瓶添加约2~3mL,T75 cm2 培养瓶约4~5 mL) 洗涤细胞1~2 次,以去除残余的培养液和血清( 血清含有胰酶的抑制因子); 加入2 倍胰酶体积的完全培养液终止消化, 并轻吹打细胞数次, 使所有细胞彻底脱壁;( 注意:吹散细胞时注意要轻柔, 尽量不产生气泡或尽可能产生少量气泡。 ); 用10 mL 移液管转移细胞悬液到一支50 mL 离心管中, 同一批次的细胞可以合并收集在一起,视情况用适量PBS 将培养瓶里的残余细胞洗下来, …

2019年6月1日 · In this model spotlight we present in vivo data on Pan02 tumor model growth kinetics, response to immunomodulatory antibodies, focal radiation, and the combination of RT with immune modulatory agents tested in the syngeneic C57BL/6 mouse strain.

源井生物聚焦于crispr/cas9技术,自主研发出crispr-u™基因敲除新技术,成功将细胞的基因敲除效率提升至10-30倍,为广大科研客户 ...

Combination anti-metabolite and anti-mitotic taxane based chemotherapy is the standard of care in the US, but these treatment options historically only improve overall survival by weeks. There is a critical unmet medical need for novel therapeutic approaches to treat pancreatic cancer.